

## The impact of a tax on sugar-sweetened beverages on health and health care costs: a modelling study – S3 Table

**Table S3. Results of nine diseases over the first 25 years after the introduction of the tax**

Expected numbers (with 95% uncertainty ranges) of incident cases, prevalent cases and deaths averted in the first to 25<sup>th</sup> year after implementation of a 20% tax on sugar-sweetened beverages in Australia. For incidence and mortality, numbers are for the stated year. For prevalence, they refer to the end of that year (e.g. Year 1 refers to prevalent numbers at 1 year after the tax change took effect).

	Ischaemic health disease	Hypertensive heart disease	Stroke	Type 2 diabetes mellitus	Osteo-arthritis	Colorectal cancer	Breast cancer	Endometrial cancer	Kidney cancer	Any cause
<b>INCIDENCE</b>										
Year 1	224 (157-295)	7 (4-11)	62 (31-93)	757 (379-1126)	78 (56-100)	17 (8-27)	16 (10-21)	5 (3-7)	8 (6-11)	
Year 5	237 (163-316)	8 (4-13)	68 (33-105)	810 (394-1245)	83 (60-106)	19 (9-30)	17 (11-23)	6 (4-8)	9 (6-12)	
Year 10	251 (171-339)	9 (5-15)	75 (36-118)	864 (410-1369)	89 (63-115)	21 (10-32)	18 (12-24)	7 (4-10)	10 (7-14)	
Year 15	254 (170-348)	11 (5-18)	80 (38-128)	880 (411-1413)	92 (65-120)	22 (10-34)	18 (12-25)	7 (4-11)	11 (7-15)	
Year 20	240 (159-329)	12 (6-20)	75 (34-120)	740 (348-1175)	89 (62-117)	22 (9-35)	18 (11-24)	8 (5-11)	11 (7-16)	
Year 25	208 (137-285)	13 (6-21)	66 (29-109)	542 (258-841)	83 (56-110)	21 (8-34)	16 (10-22)	7 (4-11)	11 (7-16)	
Cumulative 0-25	6,350 (4312-8591)	269 (135-436)	1,895 (897-3016)	20,088 (9671-31487)	2,227 (1578-2893)	527 (237-834)	441 (290-598)	172 (105-250)	262 (171-365)	
<b>PREVALENCE</b>										
Year 1	111 (78-146)	3 (2-5)	30 (15-46)	378 (189-562)	39 (28-50)	8 (4-13)	8 (5-10)	2 (2-3)	4 (3-5)	
Year 5	1,009 (703-1331)	23 (12-35)	268 (133-408)	3,400 (1679-5123)	342 (247-444)	70 (33-108)	67 (44-90)	22 (14-31)	34 (23-47)	
Year 10	2,095	37	546	7,191	701	129	136	48	67	

## The impact of a tax on sugar-sweetened beverages on health and health care costs: a modelling study – S3 Table

Year 15	(1457-2780) 3,082	(20-59) 48	(266-845) 798	(3485-11030) 10,861	(501-908) 1,020	(60-202) 172	(89-184) 197	(30-67) 73	(44-92) 94
Year 20	(2141-4103) 3,891	(24-77) 57	(383-1258) 1,002	(5176-16879) 13,999	(719-1332) 1,271	(77-271) 198	(128-267) 246	(45-104) 96	(61-130) 114
Year 25	(2688-5215) 4,426	(28-94) 62	(473-1605) 1,118	(6646-22016) 15,875	(886-1672) 1,427	(84-319) 208	(159-337) 279	(58-139) 113	(74-159) 126
	(3047-5939)	(29-105)	(521-1809)	(7480-25050)	(979-1896)	(82-342)	(176-385)	(68-166)	(81-177)

### MORTALITY

Year 1	1 (1-2)	0 (0-1)	1 (0-1)	0 (0-1)	0 (0-0)	0 (0-1)	0 (0-0)	0 (0-0)	6 (4-9)	4 (3-4)
Year 5	12 (7-16)	3 (1-4)	6 (3-10)	5 (2-7)	0 (0-0)	3 (2-5)	1 (1-2)	0 (0-0)	7 (4-10)	30 (24-37)
Year 10	25 (16-35)	4 (2-7)	13 (6-20)	11 (5-17)	0 (0-0)	6 (3-9)	2 (2-3)	1 (0-1)	7 (4-11)	59 (46-73)
Year 15	39 (25-54)	6 (3-9)	19 (9-30)	18 (8-28)	0 (0-0)	8 (4-13)	3 (2-5)	1 (1-1)	8 (5-12)	83 (65-103)
Year 20	53 (34-74)	7 (3-11)	26 (11-41)	26 (12-41)	0 (0-0)	9 (4-15)	4 (3-6)	1 (1-2)	8 (5-13)	101 (79-126)
Year 25	64 (41-90)	7 (4-13)	30 (13-50)	33 (15-52)	0 (0-0)	10 (4-16)	4 (3-6)	1 (1-2)	8 (4-12)	107 (83-133)
Cumulative 0-25	839 (535-1173)	125 (63-202)	419 (192-668)	396 (182-625)	1 (0-1)	162 (70-258)	69 (45-94)	20 (12-28)	195 (112-292)	1,606 (1252-1986)